Bookmark and Share

Hematology Oncology

Pediatric Hematology Oncology Fellowship

The Program

The Section of Pediatric Hematology Oncology has a long and proud history at UAMS and Arkansas Children's Hospital.  Dr. Dasilee Berry was one of the first Board Certified Pediatric Hematologist Oncologist and began the program in Arkansas in 1964. The current Chief of Pediatric Hematology Oncology, David Becton is the second leader at ACH in the history of the program.

We diagnose more than 100 new patients with various cancers a year.  We provide comprehensive care to these patients with complete support including Critical Care, Cardiology, Renal, Radiation Therapy, Laboratory and Blood Bank Support, Pediatric Surgery, Orthopedic Oncology, and Neuro-Oncology.  The Bleeding disorders and Thrombosis Clinic follows more than 150 patients with Hemophilia and 250 patients with von Willebrand's disease.  We also see on average more than 24 new thrombophilia patients a year.  Our hemoglobinopathies program follows more than 400 patients with Sickle Cell disease and other disorders.  We have a large Southeast Asian population and the largest group of Marshallese Islanders outside the Marshall Islands in Arkansas. These ethnic groups add diversity to our complex Red Blood Cell Disorders group.

Fellows will have access to various educational opportunities including the core curriculum, Tumor Board, Journal Club, various administrative activities, and faculty development programs.

Arkansas Children's Hospital is one of the 10 largest free standing Children's Hospital in the USA.  We have a dedicated clinic and inpatient facility for our patients and a new tower is under construction to expand our facilities even more.

Contact Us

For further information and an application, please contact:

Kimo Stine, MD
Professor, Department of Pediatrics
Fellowship Program Director
College of Medicine
University of Arkansas for Medical Sciences
Arkansas Children's Hospital
1 Children's Way, Slot 512-10
Little Rock, Arkansas 72202-3591
Phone: (501) 364-1494
E-mail:

This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Faculty

David Becton, MD, Professor of Pediatrics graduated from Hendrix College and went on to attend the University of Arkansas for Medical Sciences.  He received his MD degree in 1979.  He completed a residency in Pediatrics at UAMS/ACH in 1982 where he also served as the Chief Resident.  Dr. Becton completed his fellowship in Pediatric Hematology Oncology at Duke University in 1985.  Dr. Becton's primary area of interest is vascular malformations, rare blood disorders, and AML.

Amir Mian, MD, is an Assistant Professor of Pediatrics.  Dr. Mian received his MD degree from Allama Iqbal Medical College, Lahore, Pakistan, in 1992.  He completed a residency in Pediatrics at Shaukat-Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan in 1997; and then another residency in Pediatrics at Beth Israel Medical Center, Long Island College Hospital, New York in 2001 where he was the Chief Resident in 2001-2002.  Dr. Mian completed a fellowship in Pediatric Hematology-Oncology and Bone Marrow Transplantation at Cincinnati Children's Hospital Medical Center, 2002-2005.  Dr. Mian's primary interest includes long term follow up after bone marrow transplant, neurofibromatosis, chronic GVHD, and the epidemiology of pediatric cancer. Dr. Mian is the assistant director for the Pediatric Hematology Oncology Fellowship.

Carolyn Suzanne Saccente, MD, is an Assistant Professor of Pediatrics.  Dr. Saccente received her MD degree from the Medical University of South Carolina.  Dr. Saccente completed here internship, residency, and fellowship at the University of Alabama at Birmingham in 1995.  Her primary research interest is Sickle Cell Disease.

Robert L. Saylors, MD, is an Associate Professor of Pediatrics.  Dr. Saylors received his MD from Louisiana State University School of Medicine in 1985.  He completed his Pediatric Residency here at UAMS, Arkansas Children's Hospital in 1988.  Dr. Saylors completed his fellowship in Pediatric Hematology Oncology at Washington University School of Medicine in St. Louis, MO in 1991.  Dr. Saylors areas of interest include neuro-oncology and developmental therapeutics.

Kimo C. Stine, MD, is a Professor of Pediatrics.  He received his MD degree in 1982 from the University of Kansas where he completed his residency in 1985.  Dr. Stine did a fellowship in Pediatric Hematology-Oncology at Duke University from 1985-1989.  His areas of interest include bone tumors, histiocytosis, and bleeding disorders. Dr. Stine is the Program Director for the Pediatric Hematology-Oncology fellowship.

Recent Publications

Selected recent bibliography of the Section of Pediatric Hematology-Oncology:

Kimo C. Stine MD, Robert L. Saylors MD, C. Suzanne Saccente MD, and David L. Becton MD. Treatment of Deep Vein Thrombosis with Enoxaparin in Pediatric Cancer Patients Receiving Chemotherapy. Clinical and Applied Thrombosis and Hemostasis, In press (Vol 13)2007.

Ullah S., Schmitz ML, Stine KC, Johnson CE, Faulkner SC, Drummon-Webb JJ.  Post Cardiopulmonary bypass coagulopathy in a neonate with a family history of von Willebrand's Disease.  The Journal of Cardiothoracic and Vascular Anesthesia 20(4):576-579, 2006 (August)

Bernstein M, Devidas, M, Lafreniere D, Souid A-K, Meyers P, Gebhardt M, Stine K, Nicholas R, Perlman E, Dubowy R, Wainer I, Link M, Goorin A, Grier H.  Intensive Therapy with Growth Factor Support for Patients with Ewing Tumor Metastatic at Diagnosis, POG/CCG Phase II Study 9457: A Report from the Children's Oncology Group. Journal Clinical Oncology 24:152-159, 2006.

Becton D., Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Sikic BI, Arceci RJ, Weinstein H.  Randomized use of cyclosporine A (CSA) to modulate p-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood 107:1315 – 1324, 2006.

Stine KC, Saylors RL, Saccente S, McClain KL, Becton DL.  Efficacy of continuous infusion 2-CDA (Cladribine) in pediatric patients with Langerhan's Cell Histiocytosis. Pediatric Blood and Cancer, 2004; 43(1):81-84 (July).

Stine KC, Saylors RL, Saccente S, and Becton DL. Long term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin and methotrexate. Medical Pediatric Oncology, 41(1): 77-78, 2003 (July, 2003).

Parham DM, Ready R, Stine K, Quiggins C, Becton D, North P.  Comparison of manual and automated leukocyte counts for determination of the absolute neutrophil count: Application to a Pediatric Oncology Clinic. Medical Pediatric Oncology, 38(3):183-186, 2002.8. Saylors RL, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R, Vietti TJ.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group Phase II study. Journal of Clinical Oncology, J. Clin Oncol 19:3463-3469, 2001.

Stine KC, Warren BA, Saylors RL, Becton DL.  KRN5500 induces apoptosis (PCD) of myeloid leukemia cell lines and patient blasts.  Leukemia Research, 24(9):741-750, September 2000.

Stine KC, Warren BA, Becton DL.  IL-12 augments NK lysis of AML cell lines. Leukemia, 12:1204-1209, 19981.  Stewart E., Rasco C., Cincotta NF, Pawletko TM, Stine KC.:  Multidisciplinary Rounds.  Case study: acute lymphocytic leukemia.  Cancer Practice, 1:94-97, 1993.

Schexnayder, S and Stine KC.  Blood Components and Transfusions. in:  Illustrated Textbook of Pediatric Emergency and critical care procedures.  (Dieckmann RA, Fiser DH, Selbst SM, eds.)  Medicina d’urgenza e Pronto Soccorso in Pediatria.  Procedure Tecniche  Manovre.  Philadelphia, PA: Harcourt Health Sciences, 2000.

Schexnayder, S and Stine KC.  Blood Components and Transfusions. In:  Illustrated Textbook of Pediatric Emergency and critical care procedures.  (Ed.  Dieckmann, R, Fiser,D., Selbst,S.  Mosby's. St. Louis. 1997, 747-761.

Stine, K.C. and Falletta, J.M. Intra-arterial chemotherapy of osteosarcoma and soft tissue sarcomas. In:  Current Practice of Interventional Radiology. (Ed. S. Kadir). B.C. Decker, Phila. 1991, 372-377.

Leissinger C, Becton DL, Cornell C, Gill JC.  StimateÒ (desmopressin acetate) nasal spray, 1.5 mg/ml, for prevention and treatment of bleeding in patients with mild hemophilia A, mild or moderate type 1 von Willebrand's disease and symptomatic carriers of hemophilia A.  Haemophilia, 7(3):258-66, 2001.

Stine KC, Warren BA, Saylors RL, Becton DL.  KRN 5500 induces apoptosis (PCD) of myeloid leukemia cell lines and patient blasts.  Leukemia Research, 24(9):741-750, September 2000.

Lacayo NJ, Lum BL, Becton DL, Weinstein H, Ravindranath Y, Chang MN, Bomgaars L, Lauer SJ, Sikic BI, Dahl GV.  Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia.  Leukemia, 16(5):920-7, 2002.

Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Boruchel S, Pratt C.  A protracted intermittent schedule of topotecan in children with refractory acute leukemia:  A Pediatric Oncology Group study.  Journal of Clinical Oncology, 20(6):1617-24, 2002.

Ge Y, Jensen T, Joiner SJ, Becton DL, et al.  High frequency of the 844ins 68 cystathionine-β-synthase gene variant in Down syndrome children with acute myeloid leukemia.  Leukemia, 16(11):2339-41, 2002.

Lacayo N, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber C, Douglas L, Wahab R, Becton D, Weinstein H, Chang M, Willman C, Radich J, Tibshirani R, Ravindranath Y, Sikic B, Dahl G. FLT3 mutations with good clinical outcome are identified by gene expression profiles at diagnosis in de novo childhood AML.   Blood, 104:2646-2654, 2004.

Stine KC, Saylors RL, Saccente S, McClain KL, Becton DL.  Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis.  Pediatric Blood & Cancer, 43(1):81-84, 2004.

Becton DL, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Sikic BI, Arceci RJ, Weinstein H.  Randomized use of Cyclosporin A (CSA) to modulate P-glycoprotein in children with AML in remission:  Pediatric Oncology Group Protocol 9421.  Blood 107:1315 – 1324, 2006.

Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, Camitta B, Carroll A, Raimondi SC, and Weinstein HJ for the Pediatric Oncology Group.  Pediatric Oncology Group (POG) Studies of Acute Myeloid Leukemia (AML):  A review of four consecutive childhood AML trials conducted between 1981 and 2000.  Leukemia, in press.

Saylors RL, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R, Vietti TJ.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group Phase II study. Journal of Clinical Oncology, J. Clin Oncol 19:3463-3469, 2001.

Ding, Y., Saylors, R.L., Brown, H., and Parham, D.H. Pulmonary inflammatory pseudotumor with HHV-8. Am. J. Surg. Pathol. 26: 1089-1092, 2002.

Naples, H.D., Stowe, C.D., Saccente, S.L., Jacobs, R.F.:  Voriconazole Serum concentrations in an infant treated for Trichosporon beigelii infection. The Pediatric Infectious Disease Journal, 22 (11): 2003

Posted:  June 24, 2008

The University of Arkansas for Medical Sciences is an equal opportunity/affirmative action employer and has a Conrad 30 waiver program. Women and minorities are encouraged to apply.

Services and Information